239 related articles for article (PubMed ID: 31104302)
21. Preferential use of central metabolism in vivo reveals a nutritional basis for polymicrobial infection.
Alteri CJ; Himpsl SD; Mobley HL
PLoS Pathog; 2015 Jan; 11(1):e1004601. PubMed ID: 25568946
[TBL] [Abstract][Full Text] [Related]
22. The type III secretion system of Proteus mirabilis HI4320 does not contribute to virulence in the mouse model of ascending urinary tract infection.
Pearson MM; Mobley HLT
J Med Microbiol; 2007 Oct; 56(Pt 10):1277-1283. PubMed ID: 17893161
[TBL] [Abstract][Full Text] [Related]
23. Flagellate and non-flagellate Proteus mirabilis in the development of experimental urinary tract infection.
Zunino P; Piccini C; Legnani-Fajardo C
Microb Pathog; 1994 May; 16(5):379-85. PubMed ID: 7815921
[TBL] [Abstract][Full Text] [Related]
24. Comparison of antibiotic resistance patterns in collections of Escherichia coli and Proteus mirabilis uropathogenic strains.
Adamus-Bialek W; Zajac E; Parniewski P; Kaca W
Mol Biol Rep; 2013 Apr; 40(4):3429-35. PubMed ID: 23283741
[TBL] [Abstract][Full Text] [Related]
25. Proteus mirabilis genes that contribute to pathogenesis of urinary tract infection: identification of 25 signature-tagged mutants attenuated at least 100-fold.
Burall LS; Harro JM; Li X; Lockatell CV; Himpsl SD; Hebel JR; Johnson DE; Mobley HL
Infect Immun; 2004 May; 72(5):2922-38. PubMed ID: 15102805
[TBL] [Abstract][Full Text] [Related]
26. Conduiturinary diversion and urinary-tract infection. I. Serum antibody titers against Escherichia coli and Proteus mirabilis in relation to urographic findings.
Bergman B; Kaijser K; Nilson AE
Scand J Urol Nephrol; 1979; 13(1):65-70. PubMed ID: 368976
[TBL] [Abstract][Full Text] [Related]
27. [Serodiagnosis and the immunological aspects of Proteus infection. IV. Serum antibody level and the pathomorphological and bacteriological indices in experimental mixed and monoinfections of the urinary tract].
Bidnenko SI; Barshteĭn IuA; Anisimova IuI; Open'ko LV
Zh Mikrobiol Epidemiol Immunobiol; 1982; (11):108-13. PubMed ID: 6760626
[TBL] [Abstract][Full Text] [Related]
28. Proteus mirabilis uroepithelial cell adhesin (UCA) fimbria plays a role in the colonization of the urinary tract.
Pellegrino R; Scavone P; Umpiérrez A; Maskell DJ; Zunino P
Pathog Dis; 2013 Mar; 67(2):104-7. PubMed ID: 23620155
[TBL] [Abstract][Full Text] [Related]
29. Biofilm Formation and Immunomodulatory Activity of Proteus mirabilis Clinically Isolated Strains.
Fusco A; Coretti L; Savio V; Buommino E; Lembo F; Donnarumma G
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212280
[TBL] [Abstract][Full Text] [Related]
30. Conduit urinary diversion and urinary-tract infection. II. Raised serum antibody titers against Escherichia coli and Proteus mirabilis in relation to bacteriologic findings.
Bergman B; Kaijser B; Nilson AE
Scand J Urol Nephrol; 1979; 13(1):71-7. PubMed ID: 368977
[TBL] [Abstract][Full Text] [Related]
31. Indwelling Urinary Catheter Model of Proteus mirabilis Infection.
Smith SN; Armbruster CE
Methods Mol Biol; 2019; 2021():187-200. PubMed ID: 31309506
[TBL] [Abstract][Full Text] [Related]
32. Clonal relatedness of Proteus mirabilis strains causing urinary tract infections in companion animals and humans.
Marques C; Belas A; Aboim C; Trigueiro G; Cavaco-Silva P; Gama LT; Pomba C
Vet Microbiol; 2019 Jan; 228():77-82. PubMed ID: 30593384
[TBL] [Abstract][Full Text] [Related]
33. d-Serine Degradation by Proteus mirabilis Contributes to Fitness during Single-Species and Polymicrobial Catheter-Associated Urinary Tract Infection.
Brauer AL; White AN; Learman BS; Johnson AO; Armbruster CE
mSphere; 2019 Feb; 4(1):. PubMed ID: 30814316
[No Abstract] [Full Text] [Related]
34. Visualization of Proteus mirabilis morphotypes in the urinary tract: the elongated swarmer cell is rarely observed in ascending urinary tract infection.
Jansen AM; Lockatell CV; Johnson DE; Mobley HL
Infect Immun; 2003 Jun; 71(6):3607-13. PubMed ID: 12761147
[TBL] [Abstract][Full Text] [Related]
35. Proteus mirabilis isolates of different origins do not show correlation with virulence attributes and can colonize the urinary tract of mice.
Sosa V; Schlapp G; Zunino P
Microbiology (Reading); 2006 Jul; 152(Pt 7):2149-2157. PubMed ID: 16804188
[TBL] [Abstract][Full Text] [Related]
36. Treatment of mice with staphylococcal enterotoxin B enhances resolution of an induced Escherichia coli urinary tract infection and stimulates production of proinflammatory cytokines.
Morin MD; Hopkins WJ
Infect Immun; 1998 Jun; 66(6):2466-70. PubMed ID: 9596704
[TBL] [Abstract][Full Text] [Related]
37. Virulence determinants of uropathogenic Escherichia coli and Proteus mirabilis.
Mobley HL; Island MD; Massad G
Kidney Int Suppl; 1994 Nov; 47():S129-36. PubMed ID: 7869662
[TBL] [Abstract][Full Text] [Related]
38. Mannose-resistant Proteus-like fimbriae are produced by most Proteus mirabilis strains infecting the urinary tract, dictate the in vivo localization of bacteria, and contribute to biofilm formation.
Jansen AM; Lockatell V; Johnson DE; Mobley HL
Infect Immun; 2004 Dec; 72(12):7294-305. PubMed ID: 15557655
[TBL] [Abstract][Full Text] [Related]
39. Serum immunoglobulin response and protection from homologous challenge by Proteus mirabilis in a mouse model of ascending urinary tract infection.
Johnson DE; Bahrani FK; Lockatell CV; Drachenberg CB; Hebel JR; Belas R; Warren JW; Mobley HL
Infect Immun; 1999 Dec; 67(12):6683-7. PubMed ID: 10569791
[TBL] [Abstract][Full Text] [Related]
40. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections.
Asadi Karam MR; Shirzad AM; Habibi M; Bouzari S
Int Immunopharmacol; 2018 May; 58():40-47. PubMed ID: 29549718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
